Chronic graft-versus-host disease is a complication of allogeneic stem cell or bone marrow transplantation in which donor immune cells attack the recipient's body. It can affect the skin, mouth, eyes, liver, lungs, joints, and other organs.
Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.
Researchers developed BIOPREVENT, an AI-based tool that predicts chronic graft-versus-host disease and transplant-related mortality in stem cell and bone marrow transplant patients by analyzing blood biomarkers and clinical data collected 90-100 days post-transplant.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07535008 |
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease |
RECRUITING | NA |
| NCT07135973 |
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07127926 |
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD |
RECRUITING | |
| NCT07116031 |
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) |
RECRUITING | PHASE2 |
| NCT07012304 |
Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy |
RECRUITING | PHASE1/PHASE2 |
| NCT07011810 |
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease |
RECRUITING | PHASE2 |
| NCT06695507 |
Upfront Ruxolitinib for Chronic Graft-vs-host Disease |
TERMINATED | PHASE1 |
| NCT06663722 |
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease |
RECRUITING | PHASE2 |
| NCT06616415 |
A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06300320 |
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
RECRUITING | PHASE2 |
